EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
-12.57%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$3.2B
AUM Growth
+$3.2B
(+2%)
Cap. Flow
+$674M
Cap. Flow
% of AUM
21.1%
Top 10 Holdings %
Top 10 Hldgs %
58.79%
Holding
97
New
22
Increased
20
Reduced
15
Closed
11
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$162M |
| 2 |
Zai Lab
ZLAB
|
$97.8M |
| 3 |
Arvinas
ARVN
|
$92.4M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$71M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$64.7M |
Top Sells
| 1 |
CRISPR Therapeutics
CRSP
|
$81.7M |
| 2 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
$77.3M |
| 3 |
Arcus Biosciences
RCUS
|
$71.3M |
| 4 |
Protagonist Therapeutics
PTGX
|
$53.5M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$40M |
Sector Composition
| 1 | Healthcare | 99.16% |
| 2 | Financials | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Voyager Therapeutics
VYGR
$204M
| $27.1M | 0.85% |
3,557,507
| – | – |
|
|
BCYC
27
Bicycle Therapeutics
BCYC
$492M
| $24M | 0.75% |
+547,453
| New | +$24M |
|
28
Edgewise Therapeutics
EWTX
$1.54B
| $22.9M | 0.72% |
2,359,808
+1,080,633
| +84% | +$10.5M |
|
29
Exelixis
EXEL
$9.95B
| $21.6M | 0.67% |
+951,333
| New | +$21.6M |
|
30
Janux Therapeutics
JANX
$1.38B
| $20.4M | 0.64% |
1,421,319
+9,344
| +0.7% | +$134K |
|
31
Geron
GERN
$893M
| $19.4M | 0.61% |
+14,285,714
| New | +$19.4M |
|
32
Ovid Therapeutics
OVID
$94.6M
| $19.2M | 0.6% |
6,117,400
+35,200
| +0.6% | +$111K |
|
|
SWTX
33
DELISTED
SpringWorks Therapeutics
SWTX
| $18.4M | 0.58% |
+325,881
| New | +$18.4M |
|
34
Oric Pharmaceuticals
ORIC
$1.03B
| $18.3M | 0.57% |
3,418,068
-50,876
| -1% | -$272K |
|
35
Ventyx Biosciences
VTYX
$184M
| $17.6M | 0.55% |
1,300,000
| – | – |
|
36
Crinetics Pharmaceuticals
CRNX
$3.26B
| $17.3M | 0.54% |
790,209
+200,040
| +34% | +$4.39M |
|
37
Arcutis Biotherapeutics
ARQT
$1.91B
| $17.2M | 0.54% |
+895,503
| New | +$17.2M |
|
|
SURF
38
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $13.7M | 0.43% |
+4,653,000
| New | +$13.7M |
|
39
PMV Pharmaceuticals
PMVP
$82.1M
| $13.5M | 0.42% |
649,786
+599,786
| +1,200% | +$12.5M |
|
|
HOOK
40
DELISTED
HOOKIPA Pharma
HOOK
| $11.4M | 0.36% |
+500,000
| New | +$11.4M |
|
|
KDNY
41
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $11.3M | 0.35% |
+690,000
| New | +$11.3M |
|
|
AKUS
42
DELISTED
Akouos, Inc. Common Stock
AKUS
| $9.39M | 0.29% |
1,975,984
| – | – |
|
|
43
Protagonist Therapeutics
PTGX
$3.62B
| $9.04M | 0.28% |
381,711
-2,257,995
| -86% | -$53.5M |
|
44
Aligos Therapeutics
ALGS
$75.1M
| $8.49M | 0.27% |
157,934
+154,292
| +4,236% | +$8.29M |
|
|
NGM
45
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $8.25M | 0.26% |
+541,108
| New | +$8.25M |
|
|
IGMS
46
DELISTED
IGM Biosciences
IGMS
| $7.98M | 0.25% |
+298,597
| New | +$7.98M |
|
47
Erasca
ERAS
$406M
| $5.84M | 0.18% |
678,441
-21,559
| -3% | -$185K |
|
48
Tango Therapeutics
TNGX
$745M
| $5.78M | 0.18% |
761,971
-538,029
| -41% | -$4.08M |
|
|
FLAC
49
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
| $5.78M | 0.18% |
587,615
| – | – |
|
50
Zentalis Pharmaceuticals
ZNTL
$123M
| $5.32M | 0.17% |
+115,236
| New | +$5.32M |
|